We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-20.00 | -0.16% | 12,106.00 | 12,120.00 | 12,122.00 | 12,190.00 | 12,024.00 | 12,080.00 | 999,558 | 16:35:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 45.81B | 5.96B | 3.8415 | 31.55 | 187.98B |
RNS Number:9497S Medical Solutions PLC 08 December 2003 December 8, 2003 NEW MEDICAL SOLUTIONS SERVICE LAUNCHED WITH INITIAL CONTRACT FOR ASTRAZENECA Medical Solutions (LSE: MLS), the cancer diagnostics company, announced today a major contract with AstraZeneca to provide specialist biomarker assessment services for the development of new cancer drugs. It is the first major contract the Company has signed for this important new service to both the pharmaceutical and biotechnology industries. By the end of this year there will be over 600 compounds in early phase development for cancer, the majority of which target specific molecules and so can be assessed using biomarker technology. Twelve months ago, Medical Solutions introduced tissue supply services for pharmaceutical and biotechnology companies using its first fully ethically consented tissue bank at Peterborough. It now has upward of 80 agreements in place for supplying normal and diseased tissue samples for drug discovery. The Company is the largest private provider of histopathology services to the NHS in Britain and its network of 72 specialist pathologists is able to provide expert opinions on this type of tissue. Subsequently, Medical Solutions has introduced a quantitative immunohistology service to assess the dose response of human tissue biomarkers to escalating amounts of a new drug. By developing assays for a series of such markers the Company has created a novel toolkit for the global cancer pipeline. This service produces vital early performance data on new compounds when first given to patients allowing better decision making on whether to take them forward to expensive pivotal studies for registration. The discovery of tightly linked biomarkers of molecular effect also provides response surrogates for patient selection so effectively personalising cancer medicine. Such molecular signatures will eventually be incorporated into diagnostics to select drugs for routine cancer care. Charles Green, CEO of Medical Solutions said today "We are delighted to be working in this exciting area with one of the world's leading cancer companies. These new services are extremely helpful tools to industry. Our unique technologies and skilled staff will provide vital information to enable future cancer patients to receive the correct treatments as rapidly as possible." The provision of services to support the pharmaceutical and biotechnology industry represents a significant move up the value chain for Medical Solutions. The Company is currently negotiating further similar agreements. Contact: Medical Solutions Charles Green, Chief Executive Officer Tel: +44 (0) 115 973 9010 Karol Sikora, Chief Scientific Director Beattie Financial Mike Wort/ Ann-marie Wilkinson Tel: +44 (0) 20 7398 3300 Notes to Editors: Medical Solutions plc provides world leading services and technology for cancer diagnosis and pathology, supporting the Healthcare, Pharmaceutical and Biotechnology sectors. The company is one of two in the UK who can provide Liquid Based Cytology (LBC) services to the NHS. LBC was recently the subject of a recommendation by the National Institute for Clinical Excellence and agreement by the NHS that it should move all cervical cancer smear tests over to using LBC technique because of the significant increase in accuracy that can be achieved by using this new technique. The group has two major divisions. The Services Division has a range of services including Specialist Pathology, Biomaterials Resources and Expertise, and 5 Laboratories. These services are provided to the Pharma/Biotech Industry worldwide and to Healthcare providers, both public and private. The Technology Divisions' range includes specialist-imaging software for telemedicine, image analysis and quantitation, and the SurePath liquid based cytology system referred to above. This division is also key in supporting its' Service divisions offerings to both the Drug Development market and the Healthcare market. The combination of world-renowned expertise, state of the art reference laboratory facilities and innovative imaging technology puts Medical in a unique position. This information is provided by RNS The company news service from the London Stock Exchange END CNTNKPKNABDDCBK
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions